Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Fiziol Zh (1994) ; 58(5): 3-13, 2012.
Artículo en Ucraniano | MEDLINE | ID: mdl-23233941

RESUMEN

The study was conducted in normotensive and spontaneously hypertensive rats anesthetized with urethane (1600 mg/kg of animal weight, intraperitoneally). It has been shown that in normotensive rats, injections of a specific inhibitor of Na+, K(+)-ATPase ouabain (10(-8)-10(-5) mol/l) in the populations of the neurons within nucleus of the solitary tract (NTS), paramedian reticular nucleus (PMn) and lateral reticular nucleus (LRN) were accompanied by the development of the hypertensive responses in a dose-dependent fashion. These data suggest that Na+, K(+)-ATPase of the neuron somatic membranes in the medullary cardiovascular nuclei is involved in neural control of the cardiovascular function, and its inhibition by microinjections of ouabain promotes the development of hypertension. In contrast to normotensive rats, ouabain injected in the medullary nuclei of spontaneously hypertensive animals induced either enhanced hypertensive or hypotensive responses. Biochemical analysis revealed that the activity of Na+, K(+)-ATPase in the microsomal fraction of the medulla oblongata of spontaneously hypertensive rats significantly exceeded its activity in the medulla oblongata of normotensive animals. Possible mechanisms of ouabain effects in spontaneously hypertensive rats have being discussed. Activation of Na+, K(+)-ATPase activity of the cardiovascular neurons with asparkam injections in the medullary nuclei resulted in hypotensive responses in both normotensive and spontaneously hypertensive rats.


Asunto(s)
Hipertensión/enzimología , Neuronas/efectos de los fármacos , Núcleo Olivar/efectos de los fármacos , Formación Reticular/efectos de los fármacos , ATPasa Intercambiadora de Sodio-Potasio/metabolismo , Núcleo Solitario/efectos de los fármacos , Animales , Presión Sanguínea/efectos de los fármacos , Cardiotónicos/administración & dosificación , Activación Enzimática/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Hipertensión/fisiopatología , Inyecciones Intraventriculares , Microinyecciones , Neuronas/enzimología , Núcleo Olivar/enzimología , Ouabaína/administración & dosificación , Aspartato de Magnesio y Potasio/administración & dosificación , Aspartato de Magnesio y Potasio/análogos & derivados , Ratas , Ratas Endogámicas SHR , Formación Reticular/enzimología , ATPasa Intercambiadora de Sodio-Potasio/antagonistas & inhibidores , Núcleo Solitario/enzimología
2.
Anesteziol Reanimatol ; (3): 8-13, 2011.
Artículo en Ruso | MEDLINE | ID: mdl-21853612

RESUMEN

UNLABELLED: The purpose of the study is to examine the relationship between the concentration of magnesium in plasma and vascular reactions during cardiac surgery. MATERIALS AND METHODS: The study included 77 patients with coronary artery disease who underwent myocardial revascularization surgery. In the first group (n = 44) during the entire operation infusion solution "potassium and magnesium asparginate" (Berlin-Chemie) was carried out at a rate of 1.5-2 ml/kg/h, in the second group (n = 33) patients were injected magnesium free crystalloid solutions. An analysis of central hemodynamics (PiCCO Plus) and microcirculation (laser Doppler flowmetry LASMA) was carried out. CONCLUSION: Maintenance of normal concentrations of magnesium in blood plasma reduces the incidence of episodes of intraoperative hypertension and improves peripheral microcirculation.


Asunto(s)
Anestesia General , Cardiotónicos/sangre , Hemodinámica/efectos de los fármacos , Magnesio/sangre , Revascularización Miocárdica/métodos , Adulto , Anciano , Cardiotónicos/administración & dosificación , Cardiotónicos/uso terapéutico , Soluciones Cristaloides , Circulación Extracorporea , Femenino , Humanos , Hipertensión/prevención & control , Complicaciones Intraoperatorias/prevención & control , Soluciones Isotónicas , Magnesio/administración & dosificación , Magnesio/uso terapéutico , Masculino , Microcirculación/efectos de los fármacos , Persona de Mediana Edad , Aspartato de Magnesio y Potasio/administración & dosificación , Aspartato de Magnesio y Potasio/sangre , Aspartato de Magnesio y Potasio/uso terapéutico , Resultado del Tratamiento
3.
Anesteziol Reanimatol ; (5): 17-21, 2008.
Artículo en Ruso | MEDLINE | ID: mdl-19105253

RESUMEN

The study included 42 patients with coronary heart disease operated on the coronary arteries. A potassium and magnesium asparaginate (PMA) solution, 450-1000 ml, was injected in 30 patients for 5-7 hours; other crystalloid solutions was used in a control group (n = 12). The concentrations of potassium and magnesium were measured prior to surgery, following initial anesthesia, before and after extracorporeal circulation (EC). The measurements suggested a significant potassium and magnesium intake at surgery under EC. The use of PMA solution showed its advantage in stabilizing the study electrolytes at the main surgical stages. Inclusion of PMA into infusion therapy considerably reduced a need for an additional use of concentrated KCl solution to maintain potassium at the preoperative level. Of particular importance was the use of PMA to maintain magnesium that was held in the upper normal range throughout the operation, as shown by both the median values and an individual analysis. When PLA was not administered, the mean concentration of magnesium was consistent with that in the lower normal electrolyte range and 50% patients developed hypomagnesemia. The comparative analysis of the clinical course after EC in both groups of patients with different levels of magnesium was indicative of the better status of some hemostatic parameters with the level of magnesium being maintained in the upper normal range.


Asunto(s)
Cardiotónicos/uso terapéutico , Circulación Extracorporea , Magnesio/sangre , Revascularización Miocárdica/métodos , Aspartato de Magnesio y Potasio/uso terapéutico , Potasio/sangre , Equilibrio Hidroelectrolítico/efectos de los fármacos , Adulto , Anciano , Cardiotónicos/administración & dosificación , Enfermedad Coronaria/sangre , Enfermedad Coronaria/cirugía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Aspartato de Magnesio y Potasio/administración & dosificación , Estudios Prospectivos , Estudios Retrospectivos , Resultado del Tratamiento
4.
Eksp Klin Farmakol ; 70(1): 17-21, 2007.
Artículo en Ruso | MEDLINE | ID: mdl-17402586

RESUMEN

Injection forms of potassium (K) and magnesium (Mg) aspartate (Asp) were compared in preventing cardiac disorders caused by electrolytic disturbances, primarily low K and Mg levels (e.g. caused by the treatment with cardiac glycosides and diuretic drugs). Widely used K- and Mg-Asp preparations (asparkam, panangin, pamaton) are synthesized from aspartic acid representing a racemic mixture of L- and D-stereoisomers. Differences in metabolism and utilization of D- and L-amino acids probably influence the pharmacological properties of K and Mg L- and D-aspartates. Moreover, the pharmacologically effective doses of Mg and K salts can induce toxicity, which depends on the nature of anions. The aim of this study was to compare of antiarrhythmic action of K and Mg L-, D-, and DL-Asp stereoisomers using calcium chloride (CaCl2) and aconitine induced arrhythmia models in rats and strophanthin-K induced arrhythmia model in guinea pigs. It was found that intravenously administered K- and Mg-L-Asp exhibited higher activity compared to K- and Mg-D- and DL-Asp on the strophanthin-K, CaCl2, and aconitine induced arrhythmia models. Indeed, K- and Mg-L-Asp more effectively decreased the incidence of arrhythmias, increased the time to onset of the first arrhythmia, decreased percentage loss of rats, and increased the survival life of animals after the first arrhythmia onset in rats with arrhythmias induced by strophanthin-K and CaCl2 as compared to K and Mg-D- and DL-Asp. At the same time K- and Mg-L-Asp was better than D- and DL-Asp with respect to acute toxicity (LD50), effective dose (ED50) and antiarrhythmic (therapeutic) ratio (LD50/ED50) in rats with aconitine-induced arrhythmia model.


Asunto(s)
Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/tratamiento farmacológico , Aspartato de Magnesio y Potasio/uso terapéutico , Aconitina/toxicidad , Animales , Antiarrítmicos/administración & dosificación , Antiarrítmicos/química , Arritmias Cardíacas/inducido químicamente , Arritmias Cardíacas/prevención & control , Cloruro de Calcio/toxicidad , Modelos Animales de Enfermedad , Cobayas , Frecuencia Cardíaca/efectos de los fármacos , Inyecciones , Aspartato de Magnesio y Potasio/administración & dosificación , Aspartato de Magnesio y Potasio/química , Ratas , Estereoisomerismo , Estrofantinas/toxicidad
5.
Klin Med (Mosk) ; 80(9): 60-2, 2002.
Artículo en Ruso | MEDLINE | ID: mdl-12416230

RESUMEN

According to estimates of WHO experts cases with diagnosed cardiomyopathy account for 40-60 per 100,000. Restrictive cardiopathy (RCP) is encountered in 5% of all the diagnosed cases of cardiomyopathy. Two patients (a mother and her daughter) with suspected of family RCP were examined using ECG, Holter ECG monitoring, echo-CG, histological tests, x-ray, blood biochemical tests. Echo-CG was most informative for verification of RCP diagnosis. The daughter had edema, enlarged liver, arterial hypertension, cardiac arrhythmia. The mother had arrhythmia, dyslipidemia. Based on the above symptoms, the patients received combined drug therapy with positive results.


Asunto(s)
Cardiomiopatía Restrictiva/genética , Adulto , Anciano , Antiarrítmicos/administración & dosificación , Antiarrítmicos/uso terapéutico , Antihipertensivos/administración & dosificación , Antihipertensivos/uso terapéutico , Aspirina/administración & dosificación , Aspirina/uso terapéutico , Atenolol/administración & dosificación , Atenolol/uso terapéutico , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Cardiomiopatía Restrictiva/complicaciones , Cardiomiopatía Restrictiva/diagnóstico , Cardiomiopatía Restrictiva/tratamiento farmacológico , Cardiotónicos/administración & dosificación , Cardiotónicos/uso terapéutico , Ecocardiografía , Electrocardiografía Ambulatoria , Femenino , Estudios de Seguimiento , Hemodinámica , Humanos , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Niacina/administración & dosificación , Niacina/uso terapéutico , Inhibidores de Agregación Plaquetaria/administración & dosificación , Inhibidores de Agregación Plaquetaria/uso terapéutico , Aspartato de Magnesio y Potasio/administración & dosificación , Aspartato de Magnesio y Potasio/uso terapéutico , Propranolol/administración & dosificación , Propranolol/uso terapéutico , Factores de Tiempo , Vasodilatadores/administración & dosificación , Vasodilatadores/uso terapéutico
6.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 16(4): 210-2, 1996 Apr.
Artículo en Chino | MEDLINE | ID: mdl-9206242

RESUMEN

Sixty chronic active hepatitis patients complicated with hyperbilirubinemia (total bilirubin > 171 mumol/L) were treated with combined treatment of Ganyan IV and Western medicine. The curative effect was compared with that treated with Western medicine alone as control (56 cases). Result showed that the effect of combined therapy group was much better than that of the control in eliminating the jaundice, descending the alanine transaminase (ALT) and improving the reversed A/G ratio (P < 0.05-0.001). In experimental studies, Ganyan IV was applied to the mice with acute liver damage formed by CCl4. It also showed significant effect on reducing total bilirubin and elevating the serum albumin statistically as compared with control (P < 0.05 = 0.01). In addition Ganyan IV could accellerating the bile excretion of normal as well as of liver damaged rats significantly. It was concluded that the Ganyan IV has the effects of treating jaundice, descending transaminase, elevating serum albumin and improving A/G ratio.


Asunto(s)
Medicamentos Herbarios Chinos/administración & dosificación , Hepatitis Crónica/tratamiento farmacológico , Hiperbilirrubinemia/tratamiento farmacológico , Adolescente , Adulto , Animales , Tetracloruro de Carbono , Enfermedad Hepática Inducida por Sustancias y Drogas , Quimioterapia Combinada , Femenino , Hepatitis Crónica/complicaciones , Humanos , Hiperbilirrubinemia/etiología , Sulfato de Magnesio/administración & dosificación , Masculino , Ratones , Persona de Mediana Edad , Aspartato de Magnesio y Potasio/administración & dosificación , Distribución Aleatoria , Ratas , Ratas Wistar
7.
Int J Sport Nutr ; 5(2): 102-9, 1995 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-7670449

RESUMEN

This study examined the effects of aspartate supplementation (ASP) on plasma ammonia concentrations ([NH4+]) during and after a resistance training workout (RTW). Twelve male weight trainers were randomly administered ASP or vitamin C in a crossover, double blind protocol, each trial separated by 1 wk. ASP and vitamin C were given over a 2-hr period beginning 5 hr prior to the RTW. The RTW consisted of bench, incline, shoulder, and triceps presses, and biceps curls at 70% of one repetition maximum (1-RM). After the RTW a bench press test (BPT) to failure at 65% of 1-RM was used to assess performance. [NH4+] was determined preexercise, 20 and 40 min midworkout, immediately postexercise, and 15 min postexercise. Treatment-by-time ANOVAs, paired t tests, and contrast comparisons were used to identify mean differences. No significant differences were observed between treatments for [NH4+] or BPT. [NH4+] increased significantly from Pre to immediately postexercise for both the ASP and vitamin C trials. Acute ASP supplementation does not reduce [NH4+] during and after a high intensity RTW in weight trained subjects.


Asunto(s)
Amoníaco/sangre , Ejercicio Físico/fisiología , Aspartato de Magnesio y Potasio/farmacología , Adolescente , Adulto , Análisis de Varianza , Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/farmacología , Estudios Cruzados , Método Doble Ciego , Alimentos Fortificados , Humanos , Lactatos/sangre , Masculino , Aspartato de Magnesio y Potasio/administración & dosificación
8.
Vestn Otorinolaringol ; (5): 47-9, 1991.
Artículo en Ruso | MEDLINE | ID: mdl-1661458

RESUMEN

Virological and cytochemical parameters of blood leukocytes during acute stenosing laryngotracheitis in 53 children were measured, viz. succinate dehydrogenase, mitochondrial alpha-glycerophosphate dehydrogenase, acid and alkaline phosphatase, myeloperoxidase. The patients were subjected to a combined treatment which included metabolites and their cofactors. The treatment gave good results, shortening the duration and reducing the number of relapses of the disease.


Asunto(s)
Laringoestenosis/sangre , Leucocitos/enzimología , Estenosis Traqueal/sangre , Traqueítis/sangre , Fosfatasa Ácida/sangre , Enfermedad Aguda , Fosfatasa Alcalina/sangre , Activación Enzimática/efectos de los fármacos , Glicerolfosfato Deshidrogenasa/sangre , Glicerolfosfato Deshidrogenasa/deficiencia , Humanos , Lactante , Laringoestenosis/complicaciones , Peroxidasa/sangre , Peroxidasa/deficiencia , Aspartato de Magnesio y Potasio/administración & dosificación , Aspartato de Magnesio y Potasio/farmacología , Riboflavina/administración & dosificación , Riboflavina/farmacología , Succinato Deshidrogenasa/sangre , Estenosis Traqueal/complicaciones , Traqueítis/complicaciones
9.
Wien Med Wochenschr ; 141(3): 64-5, 1991.
Artículo en Alemán | MEDLINE | ID: mdl-1711738

RESUMEN

In 21 patients with ventricular arrhythmias we analysed the effect of an intravenous infusion of potassium-magnesium-aspartate. It could be demonstrated that the frequency of ventricular ectopic beats significantly declined 1 hour after starting the medication. The maximum effect occurred at the 6th and 7th hour and continued until the 10th hour after starting the medication.


Asunto(s)
Antiarrítmicos , Complejos Cardíacos Prematuros/tratamiento farmacológico , Electrocardiografía Ambulatoria/efectos de los fármacos , Aspartato de Magnesio y Potasio/administración & dosificación , Electrocardiografía Ambulatoria/instrumentación , Femenino , Humanos , Infusiones Intravenosas , Masculino , Microcomputadores , Persona de Mediana Edad , Procesamiento de Señales Asistido por Computador/instrumentación
10.
J Cardiothorac Anesth ; 3(2): 176-80, 1989 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2519943

RESUMEN

In a prospective randomized double-blind study, the peripheral vascular effects of potassium chloride (KCl) and potassium-magnesium-aspartate (KMA) were compared. Twenty patients undergoing coronary artery bypass graft surgery received either 12 mmol of KCl (n = 10) or 12 mmol of KMA (n = 10) into the oxygenator of the heart-lung machine during extracorporeal circulation (ECC). The most striking difference between these two solutions was vasoconstriction following KCl administration and vasodilation after KMA injection. In the KMA group, decreases of perfusion pressure (MAP) and systemic vascular resistance (SVR), as well as changes in the oxygenator volume (dV), were significant (P less than 0.01) between the first and the fifth minutes. Maximal changes of MAP, from 72 +/- 13 to 59 +/- 12 mmHg (mean +/- SD), and SVR were recorded in the first and second minutes. Oxygenator volume changes reached their maximum (285 +/- 163 mL) in the tenth minute. In the KCl group, maximal increases in MAP, from 70 +/- 16 to 81 +/- 20 mmHg (mean +/- SD), and SVR were found in the fourth minute. Maximal changes in dV (300 +/- 315 mL) were measured in the tenth minute. Plasma epinephrine levels, which were already elevated during ECC, showed further increases in all cases in the KCl group and in most of the cases in the KMA group. The change in plasma epinephrine concentration following KCl injection was significant (P less than 0.01). No characteristic change in plasma norepinephrine was found in either of the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Epinefrina/sangre , Circulación Extracorporea , Hemodinámica/efectos de los fármacos , Norepinefrina/sangre , Cloruro de Potasio/farmacología , Aspartato de Magnesio y Potasio/farmacología , Potasio/sangre , Anciano , Análisis de Varianza , Presión Sanguínea/efectos de los fármacos , Volumen Sanguíneo/efectos de los fármacos , Método Doble Ciego , Humanos , Persona de Mediana Edad , Oxigenadores , Cloruro de Potasio/administración & dosificación , Aspartato de Magnesio y Potasio/administración & dosificación , Estudios Prospectivos , Resistencia Vascular/efectos de los fármacos
12.
Kardiologiia ; 24(3): 35-9, 1984 Mar.
Artículo en Ruso | MEDLINE | ID: mdl-6727091

RESUMEN

The effect of a series of drugs (retabolil, strophanthin, retabolil with strophanthin, retabolil with panangin , methyluracil with panangin ) on protein metabolism was investigated in 246 patients with acute myocardial infarction. Retabolil both alone and combined with panangin , and a methyluracil-- panangin combination were found to have anticatabolic and protein synthesizing effects. Strophanthin, when used in the acute period of myocardial infarction, contributes to an increase in the protein decay rate and a decrease in protein synthesis. When it is employed in combination with metabolism corrective agents (retabolil), the adverse effects of strophanthin mentioned above are eliminated.


Asunto(s)
Anabolizantes/administración & dosificación , Infarto del Miocardio/tratamiento farmacológico , Albúmina Sérica Radioyodada/metabolismo , Adulto , Anciano , Quimioterapia Combinada , Humanos , Persona de Mediana Edad , Infarto del Miocardio/metabolismo , Nandrolona/administración & dosificación , Nandrolona/análogos & derivados , Nandrolona Decanoato , Aspartato de Magnesio y Potasio/administración & dosificación , Estrofantinas/administración & dosificación , Uracilo/administración & dosificación , Uracilo/análogos & derivados
13.
Farmakol Toksikol ; 45(6): 41-5, 1982.
Artículo en Ruso | MEDLINE | ID: mdl-7151998

RESUMEN

The effects of isoptin and panangin on the collateral coronary blood flow have been examined in dogs during acute occlusion of the left coronary artery. It has been established that panangin (1 and 6 mg/kg) and isoptin (0.005 mg/kg) increase the collateral blood inflow to the ischemic zone, raise the cardiac output, and reduce the peripheral resistance. The raising of the isoptin dose up to 0.01 mg/kg inhibits the blood supply of the affected area, decreases the systolic and minute heart volumes.


Asunto(s)
Ácido Aspártico/análogos & derivados , Bloqueadores de los Canales de Calcio/administración & dosificación , Circulación Colateral/efectos de los fármacos , Circulación Coronaria/efectos de los fármacos , Enfermedad Coronaria/tratamiento farmacológico , Aspartato de Magnesio y Potasio/administración & dosificación , Verapamilo/administración & dosificación , Animales , Enfermedad Coronaria/fisiopatología , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Hemodinámica/efectos de los fármacos , Masculino
15.
Kardiologiia ; 16(12): 81-7, 1976 Dec.
Artículo en Ruso | MEDLINE | ID: mdl-64640

RESUMEN

The antiarrhythmic effect of Panangine and Strophantin was studied by way of rhythmography in patients with extrasystole of different etiology. The strophantin (0.25 mg) an Panangine (2 vials intravenously) tests, and therapeutic courses of Panagine (2 coated tablets 3 times a day for 5--7 days) or of Strophantin (0.25 mg) with Panagine (2 vials intravenously) for 7--10 days were conducted. A course of Strophantin with Panangine was given only to those patient who did not increase the number of their extrasystoles after the Strophantin test. Such a course resulted in the most striking antiarrhythmic effect (60.3% of the patients).


Asunto(s)
Antiarrítmicos/uso terapéutico , Ácido Aspártico/análogos & derivados , Complejos Cardíacos Prematuros/tratamiento farmacológico , Aspartato de Magnesio y Potasio/administración & dosificación , Estrofantinas/administración & dosificación , Administración Oral , Complejos Cardíacos Prematuros/etiología , Ensayos Clínicos como Asunto , Quimioterapia Combinada , Pruebas de Función Cardíaca , Humanos , Inyecciones Intravenosas , Aspartato de Magnesio y Potasio/uso terapéutico , Estrofantinas/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA